Quantitative Real-Time PCR for Detection of Parvovirus B19 DNA in Blood Plasma for Plasma Screening

  • M. H. G. M. Koppelman
  • H. T. M. Cuypers
Part of the Developments in Hematology and Immunology book series (DIHI, volume 37)


Human Parvovirus B 19 (PV-B 19) is a 18–26 nm small, non-enveloped, single stranded DNA virus belonging to the family Parvoviridae. The virus has a tropism for red blood cell progenitors. Most of the clinical manifestations due to viral infection are related to impairment of the functions of red blood cell progenitors (i.e. transient aplastic crisis, pure red cell aplasia) or to circulating immune complexes resulting from infection (Erythema infectiosum, rash, arthropathy). PV-B 19 is normally transmitted via the respiratory route. PV-B 19 is commonly found in blood donors. The prevalence of high viremic PV-B 19 infection among blood donors is estimated between 1:20,000 to 1:50,000 [1]. However, during micro epidemic periods the prevalence can be as high as 1:260 [1]. The high viremic period after infection is usually short and very intense with PV-B 19 loads up to 1014 copies /ml in plasma. After this initial burst of virus, infected individuals stay low viremic for a prolonged period up to several months with load <104 copies/ml in plasma. Although normally transmitted via the respiratory route, parental transmission of PV-B 19 can occur via the administration of blood components and blood derivatives. Transmission via blood components originating from a single donor occurs only rarely. The reported cases include a recipient of an infected red cell unit with thalassemia [2] and recipients who underwent bone marrow [3] or liver transplantation. These rare observations are in contrast with many reports on the transmission of PV-B 19 via blood derivatives such as clotting factor concentrates, albumin and IVIG [4].


Test Pool Respiratory Route Acceptor Fluorophore Blood Derivative Erythema Infectiosum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B 19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001; 41: 130–35.PubMedCrossRefGoogle Scholar
  2. 2.
    Zanella A, Rossi F, Cesana C, et al. Transfusion-transmitted human parvovirus B 19 infection in a thalassemic patient. Transfusion 1995; 35: 769–72.PubMedCrossRefGoogle Scholar
  3. 3.
    Cohen BJ, Beard S, Knowles WA, et al. Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion 1997; 37: 947–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999; 13: 194–204.PubMedCrossRefGoogle Scholar
  5. 5.
    Schmidt I, Blumel J, Seitz H, Willkommen H, Lower J. Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang. 2001; 81: 228–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997; 22: 176–81.Google Scholar
  7. 7.
    Boom R, Sol CJ, Salimans MM, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28: 495–503.PubMedGoogle Scholar
  8. 8.
    Saldanha J, Lelie N, Yu MW, Heath A. Establishment of the first World Health Organization International Standard for human parvovirus B 19 DNA nucleic acid amplification techniques. Vox Sang 202; 82: 24–31.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2002

Authors and Affiliations

  • M. H. G. M. Koppelman
  • H. T. M. Cuypers
    • 1
  1. 1.Sanquin Diagnostics Viral SerologyAmsterdamNL

Personalised recommendations